Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Oncimmune Holdings said it had presented positive study data at an industry conference in Barcelona.
The data were presented by professor Frank Sullivan, the chief investigator on a trial of the company's Oncimmune's EarlyCDT Lung test.
In a randomised controlled trial of 12,209 people in Scotland at high risk of developing lung cancer, it was shown that more people were diagnosed at an early stage of the disease in the two years after taking the EarlyCDT Lung test than those in the control arm who received standard clinical care.
The findings were presented at the 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Barcelona on Monday.
At 9:30am: (LON:ONC) Oncimmune Holdings Plc share price was +1p at 92p